You are here

Congress Planner

  • Feb 2017
    Feb 2017

    Zing Conferences

    A Full synopsis detailing the themes and topics of this conference will be made available in the near future. 

    Carlsbad, United States
  • Feb 2017
    Feb 2017

    Cleveland Clinic

    The 2017 International Symposium on Cranial and Spine Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) in Lake Buena Vista, Florida, will bring together world leaders in brain-, spine- and body-targeted stereotactic radiation modalities and techniques. Faculty and participants will have 3 days to discuss advances in the treatment of benign and malignant tumors involving multiple organ sites. A broad range of organ-specific technical and clinical experience will be presented with opportunities to interact with faculty and system vendors.

    Scientific abstracts will be solicited from attendees for poster presentation sessions.

    Target Audience: Radiation Oncologists, Neurosurgeons, Medical Physicists, Dosimetrists, Neuro-Oncologists, Medical Oncologists, Spine Surgeons and Neurologists.

    Lake Buena Vista, United States
  • Mar 2017
    Mar 2017

    Global Engage

    Building on the success of our 2015 and 2016 congresses, Global Engage is pleased to announce the 3rd Microbiome R&D and Business Collaboration Congress: Asia, which will be held on March 1 – 2, 2017 in Hong Kong and co-located with our 2nd Probiotics Congress. Last year’s successful event attracted over 200 attendees.

    Developments in the field of metagenomics have allowed researchers to explore the diverse microbiota in the human body. Research has shown that the microbiome is linked to natural immunity, metabolism, behavioural traits, and broadly speaking, plays an instrumental role in health and disease. With large-scale collaborative projects underway and sequencing data placed in the public domain, there is a rich source of information for researchers and companies looking for opportunities in this exciting field. Increasingly, there are indications that the human microbiome is key to curative and preventative medicine so efforts are being focused on expanding investment opportunities, performing more clinical trials and spurring innovative research in this area. Coupled with an increasing focus on healthy living and a therapeutics market that is expected to grow to $1.2 trillion by 2016, microbiome research is set to make waves in the science and medical world through its application in preventative treatments, cures, therapies and supplements.

    Hong Kong, Hong Kong S.A.R., China
  • Mar 2017
    Mar 2017

    ACCELERATE Platform

    The ACCELERATE Paediatric Oncology Conference will take place on 2-3 March 2017 in Brussels.
    Formerly known as CDDF-ITCC-SIOPE Paediatric Conference, this Annual Conference allows high-level experts and representatives from academia, parents organisations, pharmaceutical companies and regulatory bodies to discuss concrete proposals to accelerate new oncology drug development for children and adolescents with cancer. Successes and failures in paediatric development, new initiatives and strategies to accelerate drug development, and the 10 years’ report of the Paediatric Regulation will be discussed during this conference.
    For more information, please see our website
    Brussels, Belgium
  • Mar 2017
    Mar 2017

    Bio events

    Dear Colleagues,

    It gives us great pleasure to invite you to attend The International Congress on Clinical Trials in Oncology and Hemato-Oncology (ICTO2017) scheduled to take place in London, UK from 16-17 March 2017.

    ICTO2017 will bring together world renowned speakers in the field of Clinical Trials and Oncology and Hemato-Oncology and this first congress will welcome oncology professionals, treatment experts, CRO’s, industry leaders and other experts to the majestic city of London.

    ICTO2017 has all the components to provide an outstanding scientific, educational and networking experience.

    The congress will focus on areas including:

    • Design of clinical trials in the new era
      • Personalized cancer medicine
      • Immuno-oncology
      • Monitoring of Trials and Statistics
      • Regulations – Survival based Medicine
      • Phase 4 Trials
      • Expanded access trials
      • Ethics and Patients’ Rights
      • Healthcare economy

    Our goal is for ICTO2017 to be the forerunner in analysis, interpretation and translation of data and knowledge relating to Clinical Trials in Oncology and Hemato-Oncology.

    We look forward to welcoming you as part of this exciting and dynamic Congress.

    London, United Kingdom
  • Mar 2017
    Mar 2017

    Fusion Conferences

    Join us for the 2nd Personalized Medicine conference taking place from 17-20 March 2017 in Cancun, Mexico to discuss precision diagnostics, cancer genomics, biomarkers, computational imaging, bioinformatics and data analytics/big data.

    Target Audience

    Scientists and physician-scientists in academia, biotech and pharmaceutical companies who would like to gain a better understanding in any of the above areas or engage in discussions on state of the art in each of these areas. Specifically, researchers working in clinical research or clinical development, biomarkers, translational research, precision therapeutics, clinical genomics, and computational biology will find this conference very appealing.

    Educational Need

    The personalized medicine space has been defined by recent regulatory approvals of targeted therapeutics in oncology and co-developed diagnostics used in patient selection. However, a broader view of personalized medicine encompasses other disease areas, newer therapeutic regimens, new therapeutic platforms and broad computational approaches. This conference will weave together many of these new approaches and their relevance to personalized medicine.


    Prof. David Roth (Director, Penn Center for Precision Medicine, University of Pennsylvania) & Dr. Michael Snyder (Professor, Stanford University).

    Confirmed Speakers

    Guna Rajagopal (Johnson & Johnson)
    Elaine Mardis (Washington University in St. Louis)
    Richard Gibbs (Baylor College of Medicine)
    Daryl Pritchard (Personalized Medicine Coalition)
    Gary Schroth (Illumina)
    Atul Butte (University of California, San Francisco)
    Jonathan Sheldon (Oracle)
    Teri Klein (Stanford University)
    George Weinstock (The Jackson Laboratory)
    Ami Bhatt (Stanford University)
    Nancy Cox (Vanderbilt University)
    Emma Lundberg (SciLifeLab)
    Marylyn Ritchie (Geisinger Health System)
    Jennifer Van Eyk (Cedars-Sinai)
    Cancun, Mexico
  • Mar 2017
    Mar 2017

    ESMO, in partnership with EACR

    The objective of the ESMO Symposium on Signalling Pathways in Cancer is to bring together basic scientists, academics, clinical researchers and industry researchers, medical and young oncologists with a special interest in the field in order to facilitate knowledge sharing through a series of interactive sessions and workshops.

    The focus of the Symposium is on the preclinical and clinical issues relevant for targeting DNA damage response and the effect of systemic and radiation therapies.

    We are pleased to announce that the 5th Symposium focusing on DNA damage response will be held in partnership with EACR.

    ESMO Scientific Co-Chair

    • Ruth Plummer, Newcastle upon Tyne, UK

    EACR Scientific Co-Chair

    • Eli Pikarsky, Jerusalem, Israel
    Sitges - Barcelona, Spain
  • Mar 2017
    Mar 2017


    Dear Colleague,

    The Biomarker Summit 2017, to be held on March 20-22, 2017 in San Diego, CA at the Hilton San Diego Resort & Spa, is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization. 

    A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector. 

    Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Summit provides a unique opportunity to gain the latest biomarker developments in four major therapeutic areas, formally organized in the following tracks:

    General Session:

    1. Plenary Keynote Session
    2. Big Data Analytics & Bioinformatics for Biomarkers Development
    3. Emerging Technologies in Biomarker Development
    4. Overcoming Challenges of Clinical Validation & Translation
    5. Panel Discussion: Companion Diagnostics Development & Partnering Strategies
    6. Overcoming Commercialization Challenges in Biomarker Development
      -Regulatory & Reimbursement Trends in Biomarker Development
      -Current Landscape of Biomarkers IP & Future Trends

    10th Oncology Biomarkers 

    1. Circulating Tumor Cells & Microvesicles
    2. Liquid Biopsy: Circulating DNA & MicroRNA
    3. Immuno-oncology Biomarkers
    4. Novel Technologies in Oncology Biomarkers

    6th Neurological Biomarkers

    1. Imaging Approaches in CNS Drug Discovery & Development
    2. CSF & Blood Based Biomarker Approaches
    3. Monitoring Progression in Neurodegenerative Disorders
    4. Novel Technologies in Neurological Biomarkers

    6th Inflammatory & Immunological Biomarkers

    1. Biomarkers of Early Progressive Inflammatory & Immunological Diseases
    2. Biomarkers & Surrogate Endpoints for Clinical Trials in Inflammatory Diseases
    3. Microbiomes in Immune Modulation & Inflammatory Diseases
    4. Inflammatory Biomarkers in Respiratory Diseases

    Cardiovascular Biomarkers

    1. Biomarker R&D in the Cardiovascular Space
    2. Heart Failure & Acute Coronary Syndromes
    3. Metabolic Syndrome & Cardiovascular Risk
    4. Novel Technologies in Cardiovascular Biomarkers


    Best regards,

    The 2017 Advisory Committee

    San Diego, United States
  • Mar 2017

    The Christie School of Oncology

    Colorectal Cancer Peritoneal Metastases : What you and your MDT Team need to know

    2 dates available:-

    Fri 24th March 2017 or Tues 21st Nov 2017

    A study day for colorectal MDT teams to discuss the management of patients with peritoneal metastatic colorectal cancer

    Intended Audience

    Oncologists, surgeons, specialist nurses, radiologists, pathologists and senior trainees working within a colorectal multidisciplinary team

     Fees    £40 Medics     £20 Non-Medics          £100 for a team of 5 participants

    Manchester, United Kingdom
  • Mar 2017
    Mar 2017

    Healthcare Education Services

    What is Introduction to Oncology and Cancer Treatment?

    Introduction to Oncology and Its Treatment is a two-day, rapid and progressive face-to-face training programme. Led by specialist physicians delegates are provided with a comprehensive overview of Oncology. This course equips attendees with the knowledge to discuss Oncology and Cancer treatment confidently and credibly.

    Introduction to Oncology and Cancer Treatment provides an introductory overview of the terminology and classification of cancer and the principle issues in treating various cancers.  The course is led by respected clinical experts who will discuss overall patient presentation, management, diagnosis and staging of a range of major tumours. The issues of oncology trials will be discussed. Group discussion and question and answer sessions are integral to the course. This oncology programme is aimed specifically at the pharmaceutical, medical technology and biotechnology and associated healthcare industries.

    What does this oncology training course include?

    • A review of commonly available anti-cancer drugs with emphasis on mode of action, dose intensity and chemotherapy regimes with particular focus on Immunotherapies
    • The treatment of major tumour types: breast, lung, upper gastrointestinal (GI), colorectal, prostate, ovarian and melanoma. Each session is presented by clinicians active in these areas. Following each session our experts will lead delegates in interactive group discussion on the key issues relating to effective management of each tumour type
    • New drug development and identification
    • New pharmacological targets of particular interest and value.
    • Clinical trial design issues are also included.

    Topics included in this oncology training:

    • Cancer: terminology and classification
    • Clinical trial issues in oncology
    • Introduction to treatment and management of cancer
    • New developments in cancer therapy
    • Introduction to the major tumour types including; breast, lung, upper gastrointestinal (GI), colorectal, prostate, ovarian and melanoma

    Faculty includes:

    Dr David Chao, Consultant in Medical Oncology, Royal Free Hospital, London, UK
    Dr Mark Harrison, Clinical Oncologist, Mount Vernon Hospital, Northwood, London, UK
    Dr Rob Hughes, Consultant Oncologist, Mount Vernon Cancer Centre, Northwood, London, UK
    Dr David Miles, Consultant Medical Oncologist, Mount Vernon Hospital, Northwood, London, UK
    Dr Marianne Nicolson, Consultant Medical Oncologist, Aberdeen Royal Infirmary, Aberdeen, UK
    Professor Jaap Verweij, Erasmus University Medical Center, Rotterdam, The Netherlands

    Kensington, United Kingdom


Search this site

Search form

ECCO2017 Symposium

Joining a conversation on the treatment evolution in advanced GI malignancies: yesterday, today, and tomorrow

Official Sponsored Satellite Symposium at ECCO 2017: European Cancer Congress, 29 January 18:45 – 20:15


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Featured Content

New Book Content

This online Resource Centre has been sponsored by Lilly Oncology

Note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subject to an independent editorial review.